According to US officials, there is "clear-cut" evidence that Remdesivir can help people recover from the coronavirus. The drug cut the duration of symptoms from 15 days down to 11 in clinical trials at hospitals around the world. The full details have not been published yet. The California-based pharma company Gilead Sciences on Wednesday said that the preliminary results showed that 50% of the COVID-19 patients treated with a 5-day dosage of Remdesivir improved and more than half were discharged from the hospital within two weeks. A phase three clinical trial is said to be the final step in the process of the drug approval

The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.